NVIDIA Expects Profit Forecast to Exclude Chinese Market Due to US Chip Control

Nvidia CEO Huang Renxun stated on Thursday (June 12) that due to the strict chip sales restrictions imposed by the United States on China, Nvidia will no longer include the Chinese market in its revenue and profit forecasts.

When asked by a CNN reporter whether the US would lift the chip export controls after this week’s trade talks in London, Huang Renxun replied, “I am not hopeful about this.” “I have informed all investors and shareholders that our forecasts will no longer include the Chinese market.”

According to a Reuters exclusive report in May, Nvidia will launch a new artificial intelligence chip set specifically for the Chinese market. The price will be much lower than the restricted H20 model exported recently. The new AI chip set is planned to begin mass production as early as June.

Meanwhile, the semiconductor giant continues to expand globally in order to solidify its position as a key player in artificial intelligence.

On Wednesday (June 11), the ninth edition of the VivaTech technology innovation exhibition opened in Paris, France. Huang Renxun and French President Emmanuel Macron jointly announced at the tech expo that Nvidia will collaborate with French artificial intelligence company Mistral to build an artificial intelligence cloud platform called “Mistral Compute” using 18,000 of Nvidia’s most advanced super chips.

In addition, Huang Renxun also announced plans to increase investment in Europe and unveiled a series of collaboration projects with European companies, including the establishment of its first industrial artificial intelligence cloud platform in Germany.

Furthermore, Huang Renxun introduced plans to expand technical centers in seven countries. The Blackwell architecture will support new European artificial intelligence infrastructure projects, open the Nvidia computing market platform for European companies, assist in multi-language AI model development, and help companies like Novo Nordisk engage in drug research and development.